Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

Fusen Pharmaceutical Company Limited
福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the "**EGM**") of Fusen Pharmaceutical Company Limited (the "**Company**") will be held at Units 5906–5912, 59th Floor, The Center, 99 Queen's Road Central, Hong Kong, on Thursday, 9 July 2026 at 2:00 p.m., for the purpose of considering and, if thought fit, passing with or without amendments, the following resolution as ordinary resolution of the Company:

ORDINARY RESOLUTION

"**THAT**

(1) the entering into and the performance of the capital increase agreement (the "**Capital Increase Agreement**") dated 18 June 2026 among Nanyang Hengsheng Enterprise Management Services Limited* (南陽衡盛企業管理服務有限公司), Wealth Depot (Hong Kong) Limited, Nanyang Industrial Investment Health Industry Group Co., Ltd.* (南陽產投健康產業集團有限公司)("**Nanyang Industrial Investment**"), Henan Xisheng Industrial Development Co., Ltd.* (河南淅勝產業發展有限責任公司) ("**Henan Xisheng**", together with Nanyang Industrial Investment, the "**Investors**") and Henan Fusen Pharmaceutical Company Limited* (河南福森藥業有限公司) (the "**Target Company**"), in relation to the subscription of the newly increased registered capital of the Target Company by the Investors with an aggregate amount of RMB300 million in accordance with the Capital Increase Agreement (the "**Capital Increase**"), and the transactions contemplated thereunder (including the Capital Increase) be and are hereby approved, confirmed and ratified; and

(2) any one or more of the directors of the Company be and are hereby authorised to do all such further acts and things, negotiate, approve, agree, sign, initial, ratify and/or execute such further documents which in their opinion may be necessary or desirable and take all steps which in their opinion may be necessary, desirable or expedient.''

By Order of the Board
Fusen Pharmaceutical Company Limited
Cao Zhiming
Chairman and Executive Director

Hong Kong, 23 June 2026

Notes:

1. Details of the above resolution is set out in the Circular. Unless the context otherwise requires, terms used herein shall have the same meanings as defined in the Circular.

2. Any member of the Company entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote on behalf of him/her. A proxy need not be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.

3. For determining the entitlement to attend and vote at the EGM, the register of members of the Company will be closed from Monday, 6 July 2026 to Thursday, 9 July 2026, both days inclusive, during which period no transfer of shares will be registered. The record date for determining the entitlement of shareholders of the Company to attend and vote at the EGM will be Thursday, 9 July 2026. In order to be eligible to attend and vote at the EGM, all transfer of shares accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Computershare Hong Kong Investor Services Limited, Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Friday, 3 July 2026.

4. To be valid, a form of proxy, together with any power of attorney or other authority (if any) under which it is signed, or a notarially certified copy thereof, must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for holding the EGM (i.e. before 2:00 p.m. on Tuesday, 7 July 2026) or any adjournment thereof.

5. Where there are joint holders of any share, any one of such joint holders may vote, either in person or by proxy in respect of such share as if he/she were solely entitled thereto, but if more than one of such joint holders be present at the EGM, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and, for this purpose, seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint holding of such share.

6. Completion and delivery of the form of proxy will not preclude a member from attending and voting in person at the EGM.

As at the date of this notice, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.